These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 33844533)

  • 41. Synthesis, Design, and Structure⁻Activity Relationship of the Pyrimidone Derivatives as Novel Selective Inhibitors of
    Xu L; Li W; Diao Y; Sun H; Li H; Zhu L; Zhou H; Zhao Z
    Molecules; 2018 May; 23(6):. PubMed ID: 29794978
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Potent human dihydroorotate dehydrogenase inhibitory activity of new quinoline-4-carboxylic acids derived from phenolic aldehydes: Synthesis, cytotoxicity, lipophilicity and molecular docking studies.
    Petrović MM; Roschger C; Chaudary S; Zierer A; Mladenović M; Jakovljević K; Marković V; Botta B; Joksović MD
    Bioorg Chem; 2020 Dec; 105():104373. PubMed ID: 33074120
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Discovery of potent human dihydroorotate dehydrogenase inhibitors based on a benzophenone scaffold.
    Li C; Zhou Y; Xu J; Zhou X; Liu S; Huang Z; Qiu Z; Zeng T; Gou K; Tao L; Zhong X; Yang X; Zhou Y; Su N; Chen Q; Zhao Y; Luo Y
    Eur J Med Chem; 2022 Dec; 243():114737. PubMed ID: 36115209
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Liquid phase combinatorial synthesis of 1,2,5-trisubstituted benzimidazole derivatives as human DHODH inhibitors.
    Sitwala ND; Vyas VK; Variya BC; Patel SS; Mehta CC; Rana DN; Ghate MD
    Bioorg Chem; 2017 Dec; 75():118-126. PubMed ID: 28941392
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Discovery and Optimization of Novel
    Zhou X; Gou K; Xu J; Jian L; Luo Y; Li C; Guan X; Qiu J; Zou J; Zhang Y; Zhong X; Zeng T; Zhou Y; Xiao Y; Yang X; Chen W; Gao P; Liu C; Zhou Y; Tao L; Liu X; Cen X; Chen Q; Sun Q; Luo Y; Zhao Y
    J Med Chem; 2023 Nov; 66(21):14755-14786. PubMed ID: 37870434
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Discovery of novel pyrazolo[3,4-b]pyridine scaffold-based derivatives as potential PIM-1 kinase inhibitors in breast cancer MCF-7 cells.
    Nafie MS; Amer AM; Mohamed AK; Tantawy ES
    Bioorg Med Chem; 2020 Dec; 28(24):115828. PubMed ID: 33166925
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Optimization of Tetrahydroindazoles as Inhibitors of Human Dihydroorotate Dehydrogenase and Evaluation of Their Activity and In Vitro Metabolic Stability.
    Popova G; Ladds MJGW; Johansson L; Saleh A; Larsson J; Sandberg L; Sahlberg SH; Qian W; Gullberg H; Garg N; Gustavsson AL; Haraldsson M; Lane D; Yngve U; Lain S
    J Med Chem; 2020 Apr; 63(8):3915-3934. PubMed ID: 32212728
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The emergence of dihydroorotate dehydrogenase (DHODH) as a therapeutic target in acute myeloid leukemia.
    Sykes DB
    Expert Opin Ther Targets; 2018 Nov; 22(11):893-898. PubMed ID: 30318938
    [No Abstract]   [Full Text] [Related]  

  • 49. Discovery of a new class of potent pyrrolo[3,4-c]quinoline-1,3-diones based inhibitors of human dihydroorotate dehydrogenase: Synthesis, pharmacological and toxicological evaluation.
    Dimitrijević MG; Roschger C; Lang K; Zierer A; Paunović MG; Obradović AD; Matić MM; Pocrnić M; Galić N; Ćirić A; Joksović MD
    Bioorg Chem; 2024 Jun; 147():107359. PubMed ID: 38613925
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A novel series of human dihydroorotate dehydrogenase inhibitors discovered by in vitro screening: inhibition activity and crystallographic binding mode.
    Zeng T; Zuo Z; Luo Y; Zhao Y; Yu Y; Chen Q
    FEBS Open Bio; 2019 Aug; 9(8):1348-1354. PubMed ID: 31087527
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The role of fluorine in stabilizing the bioactive conformation of dihydroorotate dehydrogenase inhibitors.
    Bonomo S; Tosco P; Giorgis M; Lolli M; Fruttero R
    J Mol Model; 2013 Mar; 19(3):1099-107. PubMed ID: 23143678
    [TBL] [Abstract][Full Text] [Related]  

  • 52. An in silico Workflow that Yields Experimentally Comparable Inhibitors for Human Dihydroorotate Dehydrogenase.
    M S; B P; Swaminathan P
    Curr Comput Aided Drug Des; 2020; 16(3):340-350. PubMed ID: 31132976
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Discovery of diverse human dihydroorotate dehydrogenase inhibitors as immunosuppressive agents by structure-based virtual screening.
    Diao Y; Lu W; Jin H; Zhu J; Han L; Xu M; Gao R; Shen X; Zhao Z; Liu X; Xu Y; Huang J; Li H
    J Med Chem; 2012 Oct; 55(19):8341-9. PubMed ID: 22984987
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evaluation of 7-arylaminopyrazolo[1,5-a]pyrimidines as anti-Plasmodium falciparum, antimalarial, and Pf-dihydroorotate dehydrogenase inhibitors.
    Azeredo LFSP; Coutinho JP; Jabor VAP; Feliciano PR; Nonato MC; Kaiser CR; Menezes CMS; Hammes ASO; Caffarena ER; Hoelz LVB; de Souza NB; Pereira GAN; Cerávolo IP; Krettli AU; Boechat N
    Eur J Med Chem; 2017 Jan; 126():72-83. PubMed ID: 27744189
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A Patent Review of Human Dihydroorotate Dehydrogenase (hDHODH) Inhibitors as Anticancer Agents and their Other Therapeutic Applications (1999-2022).
    Gehlot P; Vyas VK
    Recent Pat Anticancer Drug Discov; 2024; 19(3):280-297. PubMed ID: 37070439
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Kinetics of inhibition of human and rat dihydroorotate dehydrogenase by atovaquone, lawsone derivatives, brequinar sodium and polyporic acid.
    Knecht W; Henseling J; Löffler M
    Chem Biol Interact; 2000 Jan; 124(1):61-76. PubMed ID: 10658902
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Structure-based design, synthesis, and characterization of inhibitors of human and Plasmodium falciparum dihydroorotate dehydrogenases.
    Davies M; Heikkilä T; McConkey GA; Fishwick CW; Parsons MR; Johnson AP
    J Med Chem; 2009 May; 52(9):2683-93. PubMed ID: 19351152
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Novel Biphenyl Pyridines as Potent Small-Molecule Inhibitors Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction.
    Wang T; Cai S; Wang M; Zhang W; Zhang K; Chen D; Li Z; Jiang S
    J Med Chem; 2021 Jun; 64(11):7390-7403. PubMed ID: 34056906
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Exploring Marine-Derived Ascochlorins as Novel Human Dihydroorotate Dehydrogenase Inhibitors for Treatment of Triple-Negative Breast Cancer.
    Luo X; Cai G; Guo Y; Gao C; Huang W; Zhang Z; Lu H; Liu K; Chen J; Xiong X; Lei J; Zhou X; Wang J; Liu Y
    J Med Chem; 2021 Sep; 64(18):13918-13932. PubMed ID: 34516133
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Brequinar derivatives and species-specific drug design for dihydroorotate dehydrogenase.
    Hurt DE; Sutton AE; Clardy J
    Bioorg Med Chem Lett; 2006 Mar; 16(6):1610-5. PubMed ID: 16406782
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.